Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 12/2022

29.10.2022 | Autoimmunity (TK Tarrant, Section Editor)

Cardiac Sarcoidosis: Current Approaches to Diagnosis and Management

verfasst von: Karen Flores Rosario, Kyla Brezitski, Kelly Arps, Megan Milne, Jayanth Doss, Ravi Karra

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Cardiac sarcoidosis (CS) is an important cause of non-ischemic cardiomyopathy and has specific diagnostic and therapeutic considerations. With advances in imaging techniques and treatment approaches, the approach to monitoring disease progression and management of CS continues to evolve. The purpose of this review is to highlight advances in CS diagnosis and treatment and present a center’s multidisciplinary approach to CS care.

Recent Findings

In this review, we highlight advances in granuloma biology along with contemporary diagnostic approaches. Moreover, we expand on current targets of immunosuppression focused on granuloma biology and concurrent advances in the cardiovascular care of CS in light of recent guideline recommendations.

Summary

Here, we review advances in the understanding of the sarcoidosis granuloma along with contemporary diagnostic and therapeutic considerations for CS. Additionally, we highlight knowledge gaps and areas for future research in CS treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Young RC Jr, Rachal RE, Cowan CL Jr. Sarcoidosis—the beginning: historical highlights of personalities and their accomplishments during the early years. J Natl Med Assoc. 1984;76(9):887.
2.
Rybicki BA, Major M, Popovich J Jr, Maliank MJ, lannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145(3):234–41.CrossRef
3.
Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis. 2018;9(11):227–40.CrossRef
4.
Iwai K, Tachibana T, Takemura T, Matsui Y, Kitalchi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Pathol Int. 1993;43(7–8):372–6.CrossRef
5.
•• Rosenthal DG, Parwani P, Murray TO, Petek BJ, Benn BS, De Marco T, et al. Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis. J Am Heart Assoc. 2019;8(18):e010952. Study showing steroid-sparing agents are an effective maintenance therapy in patients with cardiac sarcoidosis after an initial response to steroids is achieved.CrossRef
6.
•• Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1304–23. Most recent guidelines on diagnosis and treatment of cardiac sarcoidosis.CrossRef
7.
Siltzbach LE. The Kveim test in sarcoidosis: a study of 750 patients. JAMA. 1961;178(5):476–82.CrossRef
8.
Adrianto I, Lin CP, Hale JJ, Levin AM, Datta I, Parker R, et al. Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility. PLoS One. 2012;7(8):e43907.
9.
Valentonyte R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet. 2005;37(4):357–64.CrossRef
10.
Hofmann S, Franke A, Fischer A, Jacobs G, Nothnagel M, Gaede KI, et al. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet. 2008;40(9):1103–6.CrossRef
11.
Izbicki G, Chavko R, Banauch GI, Weiden MD, Berger KI, Aldrich TK, et al. World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest. 2007;131(5):1414–23.CrossRef
12.
Drent M, Crouser ED, Grunewald J. Challenges of sarcoidosis and its management. N Engl J Med. 2021;385(11):1018–32.CrossRef
13.
Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol. 2016;68(4):411–21.CrossRef
14.
Pagán AJ, Ramakrishnan L. The formation and function of granulomas. Annu Rev Immunol. 2018;36:639–65.CrossRef
15.
Davis JM, Clay H, Lewis JL, Ghori N, Herbomel P, Ramakrishnan L. Real-time visualization of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos. Immunity. 2002;17(6):693–702.CrossRef
16.
James DG, Zumla A. The granulomatous disorders. Cambridge: Cambridge Univ. Press; 1999. p. 132–60.
17.
Gerke AK. Treatment of sarcoidosis: a multidisciplinary approach. Front Immunol. 2020;11:545413.CrossRef
18.
Vega LE, Espinoza LR. HIV infection and its effects on the development of autoimmune disorders. Pharmacol Res. 2018;129:1–9.CrossRef
19.
Foulon G, Wislez M, Naccache J, Blanc F, Rabbat A, Dominique I, et al. Sarcoidosis in HIV-infected patients in the era of highly active antiretroviral therapy. Clin Infect Dis. 2004;38(3):418–25.CrossRef
20.
Morris DG, Jasmer RM, Huang L, Gotway MB, Nishimura S, King TE Jr. Sarcoidosis following HIV infection: evidence for CD4 lymphocyte dependence. Chest. 2003;124(3):929–35.CrossRef
21.
Ramstein J, Broos CE, Simpson LJ, Ansel KM, Sun SA, Ho ME, et al. IFN-γ–producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med. 2016;193(11):1281–91.CrossRef
22.
Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax. 2011;66(2):144–50.CrossRef
23.
Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med. 2006;203(2):359–70.CrossRef
24.
Taflin C, Miyara M, Nochy D, Valeyre D, Naccache J, Altare F, et al. FoxP3 regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol. 2009;174(2):497–508.CrossRef
25.
Cronan MR, Beerman RW, Rosenberg AF, Saelens JW, Johnson MG, Oehlers SH, et al. Macrophage epithelial reprogramming underlies mycobacterial granuloma formation and promotes infection. Immunity. 2016;45(4):861–76.CrossRef
26.
Adams DO. The structure of mononuclear phagocytes differentiating in vivo: I. Sequential fine and histologic studies of the effect of Bacillus Calmette-Guerin (BCG). Am J Pathol. 1974;76(1):17.
27.
Cronan MR, Hughes EJ, Brewer WJ, Viswanathan G, Hunt EG, Singh B, et al. A non-canonical type 2 immune response coordinates tuberculous granuloma formation and epithelialization. Cell. 2021;184(7):1757–74 (e14).CrossRef
28.
Giblin GT, Murphy L, Stewart GC, Desai AS, Di Carli MF, Blankstein R, et al. Cardiac sarcoidosis: when and how to treat inflammation. Card Fail Rev. 2021 Mar;7.
29.
Kullberg S, Rivera NV, Abo Al Hayja M, Grunewald J, Eklund A. Changes in lung immune cells related to clinical outcome during treatment with infliximab for sarcoidosis. Clin Exp Immunol. 2020;201(1):85–93.CrossRef
30.
Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 2005;45:657.CrossRef
31.
Tamura R, Sato A, Chida K, Suganuma H. Fibroblasts as target and effector cells in Japanese patients with sarcoidosis. Lung. 1998;176(2):75–87.CrossRef
32.
Terasaki F, Yoshinaga K. New guidelines for diagnosis of cardiac sarcoidosis in Japan. Ann Nucl Cardiol. 2017;3(1):42–5.CrossRef
33.
Tavora F, Cresswell N, Li L, Ripple M, Solomon C, Burke A. Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. Am J Cardiol. 2009;104(4):571–7.CrossRef
34.
Hulsmans M, Clauss S, Xiao L, Aguirre AD, King KR, Hanley A, et al. Macrophages facilitate electrical conduction in the heart. Cell. 2017;169(3):510–22 (e20).CrossRef
35.
Nordenswan H, Lehtonen J, Ekström K, Kandolin R, Simonen P, Mäyränpää M, et al. Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block. Circ Arrhythm Electrophysiol. 2018;11(8):e006145.CrossRef
36.
Padala SK, Peaslee S, Sidhu MS, Steckman DA, Judson MA. Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis. Int J Cardiol. 2017;227:565–70.CrossRef
37.
Fussner LA, Karlstedt E, Hodge DO, Fine NM, Kalra S, Carmona EM, et al. Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centers. Eur J Heart Fail. 2018;20(12):1713–20.CrossRef
38.
Hiraga H, Iwai K, Hiroe M, Omori F, Sekiguchi M, Tachibana T. Guidelines for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases (in Japanese) Tokyo: The Japanese Ministry of Health and Welfare; 1993. Google Scholar :23–24.
39.
Hiraga H, Yuwai K, Hiroe M. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord. 2007;27(89):102.
40.
Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L, et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):19–27.
41.
Blankstein R, Waller AH. Evaluation of known or suspected cardiac sarcoidosis. Circ Cardiovasc Imaging. 2016;9(3):e000867.CrossRef
42.
•• Kawai H, Sarai M, Kato Y, Naruse H, Watanabe A, Matsuyama T, et al. Diagnosis of isolated cardiac sarcoidosis based on new guidelines. ESC Heart Fail. 2020;7(5):2662–71. This study showed how the most recent criteria for CS led to a higher diagnostic yield for CS, particularly isolated CS.CrossRef
43.
Ekström K, Lehtonen J, Nordenswan H, Mäyränpää MI, Räisänen-Sokolowski A, Kandolin R, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. Eur Heart J. 2019;40(37):3121–8.CrossRef
44.
Bressi E, Crawford TC, Bogun FM, Gu X, Ellenbogen KA, Chicos AB, et al. Arrhythmia monitoring and outcomes in patients with cardiac sarcoidosis: insights from the cardiac sarcoidosis consortium. J Am Heart Assoc. 2022;11(13):e024924.CrossRef
45.
Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138(2):299–302.CrossRef
46.
Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2007;28(24):3076–93.CrossRef
47.
Ezzeddine FM, Kapa S, Rosenbaum A, Blauwet L, Deshmukh AJ, AbouEzzeddine OF, et al. Electrogram-guided endomyocardial biopsy yield in patients with suspected cardiac sarcoidosis and relation to outcomes. J Cardiovasc Electrophysiol. 2021;32(9):2486–95.CrossRef
48.
Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109(10):1250–8.CrossRef
49.
Komada T, Suzuki K, Ishiguchi H, Kawai H, Okumura T, Hirashiki A, et al. Magnetic resonance imaging of cardiac sarcoidosis: an evaluation of the cardiac segments and layers that exhibit late gadolinium enhancement. Nagoya J Med Sci. 2016;78(4):437.
50.
•• Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120(20):1969–77. This study showed LGE on cMRI was more sensitive than prior consensus criteria for the detection of CS.CrossRef
51.
Steckman DA, Schneider PM, Schuller JL, Aleong RG, Nguyen DT, Sinagra G, et al. Utility of cardiac magnetic resonance imaging to differentiate cardiac sarcoidosis from arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2012;110(4):575–9.CrossRef
52.
Dill T. Contraindications to magnetic resonance imaging. Heart. 2008;94(7):943–8.CrossRef
53.
Bokhari S, Sheikh T. Cardiac sarcoidosis: Advantages and limitations of advanced cardiac imaging. J Nucl Cardiol. 2021:1–4.
54.
Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53(2):241–8.CrossRef
55.
Aitken M, Chan MV, Urzua Fresno C, Farrell A, Islam N, McInnes MD, et al. Diagnostic accuracy of cardiac MRI versus FDG PET for cardiac sarcoidosis: a systematic review and meta-analysis. Radiology 2022:213170.
56.
Greulich S, Gatidis S, Gräni C, Blankstein R, Glatthaar A, Mezger K, et al. Hybrid cardiac magnetic resonance/fluorodeoxyglucose positron emission tomography to differentiate active from chronic cardiac sarcoidosis. Cardiovasc Imaging. 2022;15(3):445–56.
57.
Cheung E, Ahmad S, Aitken M, Chan R, Iwanochko RM, Balter M, et al. Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis. Eur J Hybrid Imaging. 2021;5(1):1–18.CrossRef
58.
Subramanian M, Swapna N, Ali AZ, Saggu DK, Yalagudri S, Kishore J, et al. Pre-treatment myocardial 18FDG uptake predicts response to immunosuppression in patients with cardiac sarcoidosis. JACC: Cardiovasc Imaging. 2021;14(10):2008–16.
59.
Ramirez R, Trivieri M, Fayad ZA, Ahmadi A, Narula J, Argulian E. Advanced imaging in cardiac sarcoidosis. J Nucl Med. 2019;60(7):892–8.CrossRef
60.
Orii M, Hirata K, Tanimoto T, Ota S, Shiono Y, Yamano T, et al. Comparison of cardiac MRI and 18F-FDG positron emission tomography manifestations and regional response to corticosteroid therapy in newly diagnosed cardiac sarcoidosis with complete heart block. Heart Rhythm. 2015;12(12):2477–85.CrossRef
61.
Studdy P, Bird R, James DG, Sherlock S. Serum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders. Lancet. 1978;312(8104):1331–4.CrossRef
62.
Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–65.CrossRef
63.
Kraaijvanger R, Janssen Bonás M, Vorselaars AD, Veltkamp M. Biomarkers in the diagnosis and prognosis of sarcoidosis: current use and future prospects. Front Immunol. 2020;11:1443.CrossRef
64.
Kobayashi Y, Sato T, Nagai T, Hirata K, Tsuneta S, Kato Y, et al. Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis. ESC Heart Fail. 2021;8(6):5282–92.CrossRef
65.
Gungor S, Ozseker F, Yalcinsoy M, Akkaya E, Can G, Eroglu H, et al. Conventional markers in determination of activity of sarcoidosis. Int Immunopharmacol. 2015;25(1):174–9.CrossRef
66.
Baba Y, Kubo T, Kitaoka H, Okawa M, Yamanaka S, Kawada Y, et al. Usefulness of high-sensitive cardiac troponin T for evaluating the activity of cardiac sarcoidosis. Int Heart J. 2012;53(5):287–92.CrossRef
67.
Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131(7):624–32.CrossRef
68.
Kouranos V, Sharma R. Cardiac sarcoidosis: state-of-the-art review. Heart. 2021;107(19):1591–9.CrossRef
69.
Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol. 2013;29(9):1034–41.CrossRef
70.
Milburn HJ, Poulter LW, Dilmec A, Cochrane GM, Kemeny DM. Corticosteroids restore the balance between locally produced Th1 and Th2 cytokines and immunoglobulin isotypes to normal in sarcoid lung. Clin Exp Immunol. 1997;108(1):105–13.CrossRef
71.
Chiu C, Nakatani S, Zhang G, Tachibana T, Ohmori F, Yamagishi M, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005;95(1):143–6.CrossRef
72.
Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88(9):1006–10.CrossRef
73.
Nagai T, Nagano N, Sugano Y, Asaumi Y, Aiba T, Kanzaki H, et al. Effect of corticosteroid therapy on long-term clinical outcome and left ventricular function in patients with cardiac sarcoidosis. Circ J. 2015;79(7):1593–600.CrossRef
74.
Nabeta T, Hara M, Naruke T, Maemura K, Oki T, Yazaki M, et al. Clinical valuables related to resolution of complete or advanced atrioventricular block after steroid therapy in patients with cardiac sarcoidosis. J Arrhythm. 2021;37(4):1093–100.CrossRef
75.
Kato Y, Morimoto S, Uemura A, Hiramitsu S, Ito T, Hishida H. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 2003;20(2):133–7.
76.
Fazelpour S, Sadek MM, Nery PB, Beanlands RS, Tzemos N, Toma M, et al. Corticosteroid and immunosuppressant therapy for cardiac sarcoidosis: a systematic review. J Am Heart Assoc. 2021;10(17):e021183.CrossRef
77.
Banba K, Kusano KF, Nakamura K, Morita H, Ogawa A, Ohtsuka F, et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm. 2007;4(10):1292–9.CrossRef
78.
Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16(2):140–7.CrossRef
79.
•• Birnie D, Beanlands RS, Nery P, Aaron SD, Culver DA, DeKemp RA, et al. Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS-RCT). Am Heart J. 2020;220:246–52. The results of this RCT will be available in the upcoming years and will compare steroid use to steroid followed by steroid sparing agents for the treatment of CS.CrossRef
80.
Ballul T, Borie R, Crestani B, Daugas E, Descamps V, Dieudé P, et al. Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs. Int J Cardiol. 2019;276:208–11.CrossRef
81.
Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86(3):301–7.CrossRef
82.
Zhou Y, Lower EE, Li H, Costea A, Attari M, Baughman RP. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest. 2017;151(1):139–48.CrossRef
83.
•• Griffin JM, Chasler J, Wand AL, Okada DR, Smith JN, Saad E, et al. Management of cardiac sarcoidosis using mycophenolate mofetil as a steroid-sparing agent. J Card Fail. 2021;27(12):1348–58. Recent study showing mycophenalate mofetil in combination with prednisone is effective and can lead to less steroid use.CrossRef
84.
Broen JC, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol. 2020;16(3):167–78.CrossRef
85.
Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 1999;16(1):87–92.
86.
Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-α, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev. 2005;4(3):153–61.CrossRef
87.
Baker MC, Sheth K, Witteles R, et al. TNF-alpha inhibition for the treatment of cardiac sarcoidosis. In: Seminars in arthritis and rheumatism. WB Saunders; 2020 Jun 1;50(3):546–52.
88.
Harper LJ, McCarthy M, Neto MLR, Hachamovitch R, Pearson K, Bonanno B, et al. Infliximab for refractory cardiac sarcoidosis. Am J Cardiol. 2019;124(10):1630–5.CrossRef
89.
Gilotra NA, Wand AL, Pillarisetty A, Devraj M, Pavlovic N, Ahmed S, et al. Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience. J Card Fail. 2021;27(1):83–91.CrossRef
90.
•• Cundiff M, Mintz D, Pincus M, Campagna A, Nghiem L, Dou Y, et al. Treatment of Active Cardiac Sarcoidosis with TNF Alpha Inhibitors. J Card Fail. 2019;25(8, Supplement):S27–8. In this study, TNF alpha inhibition lead to improvements in inflammation and minimal adverse effects in patients with CS.CrossRef
91.
Elwazir M, Krause ML, Bois JP, Christopoulos G, Kendi AT, Cooper JLT, et al. Rituximab for the treatment of refractory cardiac sarcoidosis: a single-center experience. J Card Fail. 2022;28(2):247–58.CrossRef
92.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263–421.CrossRef
93.
•• Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):e91–220. These are the most recent arrhythmia guidelines that provide recommendations on ICD use for primary and secondary prevention in patients with CS.CrossRef
94.
Siontis KC, Santangeli P, Muser D, Marchlinski FE, Zeppenfeld K, Hoogendoorn JC, et al. Outcomes associated with catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. JAMA cardiology. 2022;7(2):175–83.CrossRef
95.
Greulich S, Seitz A, Herter D, Günther F, Probst S, Bekeredjian R, et al. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study. Eur Heart J Cardiovasc Imaging. 2021;22(7):732–41.CrossRef
96.
Rosenthal DG, Cheng RK, Petek BJ, Masri SC, Mikacenic C, Raghu G, et al. Risk of adverse cardiovascular events in cardiac sarcoidosis independent of left ventricular function. Am J Cardiol. 2020;127:142–8.CrossRef
97.
Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32(2):157–87.CrossRef
98.
Crawford TC, Okada DR, Magruder JT, Fraser C, Patel N, Houston BA, et al. A contemporary analysis of heart transplantation and bridge-to-transplant mechanical circulatory support outcomes in cardiac sarcoidosis. J Card Fail. 2018;24(6):384–91.CrossRef
99.
•• Jackson KC, Youmans QR, Wu T, Harap R, Anderson AS, Chicos A, et al. Heart transplantation outcomes in cardiac sarcoidosis. J Heart Lung Transplant. 2022;41(1):113–22. This retrospective study showed patients with CS have similar survival after heart transplantation and similar rates of graft failure and post-transplant malignancy as patients without CS.CrossRef
100.
Asleh R, Briasoulis A, Doulamis I, Alnsasra H, Tzani A, Alvarez P, et al. Outcomes after heart transplantation in patients with cardiac sarcoidosis. ESC Heart Fail. 2022;9(2):1167–74.CrossRef
101.
Yager JE, Hernandez AF, Steenbergen C, Persing B, Russell SD, Milano C, et al. Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant. 2005;24(11):1988–90.CrossRef
Metadaten
Titel
Cardiac Sarcoidosis: Current Approaches to Diagnosis and Management
verfasst von
Karen Flores Rosario
Kyla Brezitski
Kelly Arps
Megan Milne
Jayanth Doss
Ravi Karra
Publikationsdatum
29.10.2022
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 12/2022
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-022-01046-x

Weitere Artikel der Ausgabe 12/2022

Current Allergy and Asthma Reports 12/2022 Zur Ausgabe

Asthma (V Ortega, Section Editor)

Urinary Leukotriene E4 as a Biomarker in NSAID-Exacerbated Respiratory Disease (N-ERD): a Systematic Review and Meta-analysis

Anaphylaxis and Drug Allergy (M Castells, Section Editor)

Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases

Allergies and the Environment (T Moran, Section Editor)

Nature with Nurture: the Role of Intrinsic Genetic and Extrinsic Environmental Factors on Eosinophilic Esophagitis

Allergic Skin Diseases (L Fonacier, Section Editor)

Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases

Occupational Allergies (JA Poole, Section Editor)

A Clinician’s Guide to Occupational Exposures in the Military

Asthma (V Ortega, Section Editor)

Recent miRNA Research in Asthma

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise